NTLA Intellia Therapeutics Inc
Company Analysis
Latest News
🟢 Intellia Therapeutics is trading 5% up today in after-hours trading
Intellia Therapeutics is trading 5.09% up at $13.38 after closing at $12.73 on August 31, 2026, with no confirmed company-specific announcement, earnings...
🟢 Intellia Therapeutics rises 5.7% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Intellia Therapeutics is trading 5% up today; catalyst remains unconfirmed
Intellia Therapeutics is trading 5.14% up now at $13.08 on August 21, 2026, with the specific catalyst unconfirmed. - No new company-specific announcement or...
🔴 Intellia Therapeutics falls 5.5% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Intellia Therapeutics is trading 10.27% up today after positive cancer-vaccine results from Moderna, Merck
Intellia Therapeutics is trading 10.27% up at $12.79 after positive Phase 3 personalized mRNA cancer-vaccine results from Moderna and Merck lifted...
🟢 Intellia Therapeutics is trading 7.76% up today after positive Moderna and Merck cancer-vaccine results
Intellia Therapeutics is trading 7.76% up at $12.58 after biotech sentiment improved following positive Phase 3 personalized mRNA cancer-vaccine results from...
🔴 Intellia Therapeutics is trading 5% down today after risk-off selling pressured biotech stocks
Intellia Therapeutics is trading 5% down at $11.48 as broader risk-off selling pressured growth-oriented and biotechnology stocks on August 18, 2026. - The...
🟢 Intellia Therapeutics is trading 5.8% up today after positive Phase 3 HAELO results
Intellia Therapeutics is trading 5.8% up at $11.89 after investors weighed August 6 earnings against encouraging lonvo-z progress. - EPS of $0.80 matched...
Intellia Therapeutics' second quarter EPS met estimates while revenue missed; lonvo-z BLA submission remains on track for 2H 2026.
Intellia Therapeutics reported second quarter collaboration revenue of $7.7 million, a significant decrease from $14.2 million in the prior year, missing...
Intellia Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts project Intellia Therapeutics will report Q2 2026 revenue of $13.4 million and a net loss of $0.80 per share, with the current stock price of $10.68...
🟢 Intellia Therapeutics is trading 5% up today amid broad biotech sector rally
Intellia Therapeutics is trading 5% up today at $11.32 as a broad biotech rally lifts the sector. • The move appears driven by wider industry momentum, with...
🟢 Intellia Therapeutics is trading 5% up today on bargain hunting after reaching oversold levels
Intellia Therapeutics is trading 5% up at $11.47 as technical buying triggers a rebound following a sharp multi-day selloff that left shares in oversold...
🔴 Intellia Therapeutics is trading 10.0% down
Intellia Therapeutics is trading at $11.73, down 10.0% from a comparison close of $13.04 during regular trading. This is a price-action follow-up, so a...
🔴 Intellia Therapeutics is trading 6.8% down today after Wolfe Research downgraded the stock
Intellia Therapeutics is trading 6.8% down today at $12.05 after Wolfe Research downgraded the company to Underperform from Peerperform. • The firm also set a...
🔴 Intellia Therapeutics is trading 5.1% down today as safety concerns and dilution worries extend a multi-day slide
Intellia Therapeutics is trading at $12.62 (5.1% down) in after-hours trading, extending a sharp multi-day decline as investors weigh pipeline risks and...
🔴 Intellia Therapeutics is trading 5.7% down today on dilution concerns and heavy insider selling
Intellia Therapeutics is trading 5.7% down at $13.49 today as investors react to a $180 million equity offering and a heavy insider-selling profile. • The...
🔴 Intellia Therapeutics is trading 5% down today on insider selling and profit-taking
Intellia Therapeutics is trading 5% down at $14.67 as investors react to a wave of insider stock sales disclosed in early July, which has added selling...
🔴 Intellia Therapeutics Is Down 4.2% as Insider Selling Adds Pressure Following Recent Lonvo-z Driven Surge
Intellia Therapeutics is trading at $16.13 (-4.22%) as recent insider selling reports add pressure. • This comes after a significant surge in the stock over...
🔴 NTLA is trading 4.2% down today on "sell the news" reaction following Phase 3 success
• Intellia Therapeutics (NTLA) is down 4.2% today at $16.70 as traders engage in "sell the news" profit-taking after the company's recent Phase 3 success for...
🔴 NTLA is trading 4.2% down today as traders lock in gains after recent rally
NTLA is trading 4.2% down at $16.70 as investors lock in profits following a strong multi-day climb into early July. • The move appears tied to normal...